DE69435083T2 - Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen - Google Patents

Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen Download PDF

Info

Publication number
DE69435083T2
DE69435083T2 DE69435083T DE69435083T DE69435083T2 DE 69435083 T2 DE69435083 T2 DE 69435083T2 DE 69435083 T DE69435083 T DE 69435083T DE 69435083 T DE69435083 T DE 69435083T DE 69435083 T2 DE69435083 T2 DE 69435083T2
Authority
DE
Germany
Prior art keywords
receptor
binding
il8r2
peptide
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435083T
Other languages
German (de)
English (en)
Other versions
DE69435083D1 (de
Inventor
Patricia A. San Anselmo Tekamp-Olson
Guy San Francisco Mullenbach
Mary Ellen San Leandro Wernette-Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of DE69435083D1 publication Critical patent/DE69435083D1/de
Application granted granted Critical
Publication of DE69435083T2 publication Critical patent/DE69435083T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69435083T 1993-09-14 1994-09-13 Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen Expired - Lifetime DE69435083T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/121,105 US6448379B1 (en) 1993-09-14 1993-09-14 IL8 inhibitors
US121105 1993-09-14

Publications (2)

Publication Number Publication Date
DE69435083D1 DE69435083D1 (de) 2008-04-17
DE69435083T2 true DE69435083T2 (de) 2009-03-12

Family

ID=22394586

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69435083T Expired - Lifetime DE69435083T2 (de) 1993-09-14 1994-09-13 Antikörper gegen den IL-8 Rezeptor und deren therapeutische Verwendungen
DE69431843T Expired - Lifetime DE69431843T2 (de) 1993-09-14 1994-09-13 Il-8 inhibitoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69431843T Expired - Lifetime DE69431843T2 (de) 1993-09-14 1994-09-13 Il-8 inhibitoren

Country Status (11)

Country Link
US (2) US6448379B1 (cg-RX-API-DMAC7.html)
EP (3) EP1283217B1 (cg-RX-API-DMAC7.html)
JP (3) JPH09502725A (cg-RX-API-DMAC7.html)
AT (2) ATE388168T1 (cg-RX-API-DMAC7.html)
AU (1) AU697190B2 (cg-RX-API-DMAC7.html)
CA (1) CA2171289C (cg-RX-API-DMAC7.html)
DE (2) DE69435083T2 (cg-RX-API-DMAC7.html)
DK (1) DK1283217T3 (cg-RX-API-DMAC7.html)
ES (1) ES2302774T3 (cg-RX-API-DMAC7.html)
PT (1) PT1283217E (cg-RX-API-DMAC7.html)
WO (1) WO1995007934A2 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6283896A (en) * 1995-06-20 1997-01-22 Chiron Corporation Interleukin-8 receptor binding compounds
AU777766B2 (en) * 1996-07-05 2004-10-28 Cancer Research Technology Limited Inhibitors of the interaction between p53 and MDM2
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
EP0939634A4 (en) * 1996-08-15 2001-02-21 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO1998046597A1 (en) * 1997-04-14 1998-10-22 Emory University Serine protease inhibitors
ES2156534B1 (es) * 1999-02-03 2002-02-01 Smithkline Beecham Sa Nuevos inhibidores de la interaccion entre la interleuquina-8 y sus receptores
US20030186889A1 (en) * 2000-03-31 2003-10-02 Wolf-Georg Forssmann Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction
NZ541050A (en) * 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
PY1147875A (es) 2010-11-08 2015-08-03 Novartis Ag Polipéptidos de enlace de los receptores de quimiocina
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US20150224190A1 (en) 2012-07-06 2015-08-13 Mohamed Bentires-Alj Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
WO2018067548A1 (en) 2016-10-03 2018-04-12 The Children's Medicial Center Corporation Prevention and treatment of diabetic nephropathy
WO2019140150A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
IE913192A1 (en) 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
JP2866182B2 (ja) 1990-10-08 1999-03-08 日本ケミファ株式会社 エンドセリン受容体
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5856457A (en) * 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
WO1992018641A1 (en) * 1991-04-10 1992-10-29 The Trustees Of Boston University Interleukin-8 receptors and related molecules and methods
US5374506A (en) 1991-09-13 1994-12-20 The United States Of America As Represented By The Department Of Health And Human Services Amino acid sequence for a functional human interleukin-8 receptor

Also Published As

Publication number Publication date
WO1995007934A2 (en) 1995-03-23
CA2171289A1 (en) 1995-03-23
CA2171289C (en) 2007-04-10
EP1932856A2 (en) 2008-06-18
PT1283217E (pt) 2008-06-11
EP1283217B1 (en) 2008-03-05
DE69431843T2 (de) 2003-07-10
JP4122321B2 (ja) 2008-07-23
AU697190B2 (en) 1998-10-01
EP0719285A1 (en) 1996-07-03
EP0719285B1 (en) 2002-12-04
JPH09502725A (ja) 1997-03-18
DE69435083D1 (de) 2008-04-17
ATE229036T1 (de) 2002-12-15
US6436390B1 (en) 2002-08-20
JP2005023085A (ja) 2005-01-27
WO1995007934A3 (en) 1995-04-13
JP2008169227A (ja) 2008-07-24
DE69431843D1 (de) 2003-01-23
EP1932856A3 (en) 2009-09-30
ES2302774T3 (es) 2008-08-01
EP1283217A3 (en) 2003-09-17
EP1283217A2 (en) 2003-02-12
US6448379B1 (en) 2002-09-10
DK1283217T3 (da) 2008-07-07
AU7834894A (en) 1995-04-03
ATE388168T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
DE69834699T3 (de) Neues protein und verfahren zu dessen herstellung
DE69333591T2 (de) CD40CR-Rezeptor und Liganden dafür
DE69534872T2 (de) Gereinigte primate clta-8 antigene und verwandte reagenzien
DE3853636T3 (de) Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
DE69605181T2 (de) Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
DE69727382T2 (de) Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden
DE69432629T3 (de) Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE69014474T2 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
DE69316948T2 (de) Lösliche Liganden für CD40
DE60009484T3 (de) Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate
DE69231223T2 (de) Menschliche pf4a rezeptoren und ihre verwendung
DE60106394T3 (de) Humanisierte antikörper, die amyloid beta peptid sequestrieren
DE69632815T2 (de) gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER
DE60129278T2 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
DE69431843T2 (de) Il-8 inhibitoren
DE69126607T2 (de) Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
DE69626423T2 (de) Verfahren und zusammensetzung zum rekonformieren multiepitopischer antigene zum anregen einer immunantwort
DE69333039T2 (de) Monoklonaler antikörper gegen ein humanes mdr1-gen produkt, das eine resistenz gegen verschiedene medikamente erzeugt und seine verwendung
DE69736474T2 (de) Antikörper gegen einen komplex aus cd4 und einer chemokinrezeptordomäne, sowie deren verwendung gegen hiv infektionen
EP1928905B1 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
DE69426076T2 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
DE69029858T2 (de) Behandlung von einer autoimmun-krankheit
DE69728897T2 (de) Saeugetierchemokine
DE60029953T2 (de) Spezifische Antikörper gegen humanes Choriongonadotropin und deren Verwendung in Therapie und Diagnose
DE69533905T2 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition